BioNTech (BNTX) director Michael Motschmann submits initial Form 3

Rhea-AI Filing Summary

BioNTech SE director Michael Motschmann has filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director and, in the data provided, does not report any insider buy, sell, gift, or option exercise transactions.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Motschmann Michael

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ GERMANY D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Humza Bokhari, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BioNTech (BNTX) Form 3 filing by Michael Motschmann show?

The Form 3 filing shows that Michael Motschmann is a director of BioNTech SE. In the provided data, it does not list any insider purchases, sales, gifts, or option exercises, serving mainly as an initial ownership and role disclosure.

Does the BioNTech (BNTX) Form 3 report any insider buying or selling?

No insider buying or selling is reported in this Form 3 for BioNTech SE. The transaction summary indicates zero buys, zero sells, and no derivative exercises, so it functions purely as a registration of the insider’s status.

Who is the reporting person in the latest BioNTech (BNTX) Form 3?

The reporting person is Michael Motschmann, identified as a director of BioNTech SE. The filing establishes his reporting status under insider ownership rules but, in the data shown, does not describe any transactions or derivative positions.

Are there any derivative securities disclosed in this BioNTech (BNTX) Form 3?

In the data provided, the Form 3 for BioNTech SE does not list any derivative securities such as options or warrants. The derivative summary section is empty, indicating no derivative holdings or exercises are reported in this excerpt.

What is the significance of a Form 3 filing for BioNTech (BNTX) investors?

A Form 3 filing introduces an insider’s status at BioNTech SE, such as a new director. It sets a baseline for future Form 4 and Form 5 filings, which will report any subsequent insider trades or changes in beneficial ownership over time.